Wall Street analysts expect that Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) will report earnings of $0.25 per share for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Sucampo Pharmaceuticals’ earnings, with the highest EPS estimate coming in at $0.27 and the lowest estimate coming in at $0.23. Sucampo Pharmaceuticals reported earnings of $0.28 per share in the same quarter last year, which suggests a negative year over year growth rate of 10.7%. The company is expected to announce its next quarterly earnings report on Wednesday, November 8th.

On average, analysts expect that Sucampo Pharmaceuticals will report full year earnings of $1.01 per share for the current year, with EPS estimates ranging from $0.98 to $1.04. For the next fiscal year, analysts expect that the business will report earnings of $1.06 per share, with EPS estimates ranging from $0.98 to $1.14. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research firms that that provide coverage for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last announced its quarterly earnings data on Wednesday, August 2nd. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $0.06. Sucampo Pharmaceuticals had a positive return on equity of 56.58% and a negative net margin of 61.99%. The business had revenue of $59.90 million during the quarter, compared to analysts’ expectations of $56.44 million. During the same quarter last year, the business posted $0.24 EPS. The business’s quarterly revenue was up 15.3% compared to the same quarter last year.

A number of research analysts recently commented on SCMP shares. ValuEngine downgraded Sucampo Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Zacks Investment Research upgraded Sucampo Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 4th. Maxim Group set a $23.00 price target on Sucampo Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, August 2nd. TheStreet cut Sucampo Pharmaceuticals from a “c+” rating to a “d” rating in a research report on Wednesday, August 2nd. Finally, Roth Capital set a $30.00 target price on Sucampo Pharmaceuticals and gave the company a “buy” rating in a research report on Thursday, August 3rd. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $17.63.

COPYRIGHT VIOLATION NOTICE: “Zacks: Brokerages Anticipate Sucampo Pharmaceuticals, Inc. (SCMP) to Post $0.25 EPS” was reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/09/zacks-brokerages-anticipate-sucampo-pharmaceuticals-inc-scmp-to-post-0-25-eps.html.

Shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) traded up 0.41% during midday trading on Friday, hitting $12.35. The stock had a trading volume of 366,567 shares. Sucampo Pharmaceuticals has a one year low of $9.30 and a one year high of $17.55. The company’s market cap is $572.11 million. The stock has a 50 day moving average of $11.01 and a 200-day moving average of $10.67.

In related news, insider Jones W. Bryan acquired 4,700 shares of the firm’s stock in a transaction on Friday, August 4th. The shares were bought at an average cost of $10.60 per share, with a total value of $49,820.00. Following the completion of the acquisition, the insider now owns 4,700 shares of the company’s stock, valued at $49,820. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Jason Patrick Meyenburg acquired 4,000 shares of the firm’s stock in a transaction on Wednesday, September 6th. The shares were bought at an average cost of $12.13 per share, for a total transaction of $48,520.00. Following the completion of the acquisition, the insider now directly owns 30,228 shares of the company’s stock, valued at approximately $366,665.64. The disclosure for this purchase can be found here. 4.13% of the stock is owned by company insiders.

Several large investors have recently bought and sold shares of the company. Dynamic Technology Lab Private Ltd bought a new position in shares of Sucampo Pharmaceuticals in the second quarter valued at approximately $132,000. Public Employees Retirement System of Ohio raised its position in Sucampo Pharmaceuticals by 37.7% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 46,222 shares of the biopharmaceutical company’s stock worth $485,000 after purchasing an additional 12,663 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in shares of Sucampo Pharmaceuticals by 4.1% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 19,983 shares of the biopharmaceutical company’s stock valued at $209,000 after acquiring an additional 790 shares during the last quarter. State Street Corp raised its position in shares of Sucampo Pharmaceuticals by 7.3% during the 2nd quarter. State Street Corp now owns 599,420 shares of the biopharmaceutical company’s stock valued at $6,290,000 after acquiring an additional 40,929 shares during the last quarter. Finally, Dana Investment Advisors Inc. raised its position in shares of Sucampo Pharmaceuticals by 17.0% during the 2nd quarter. Dana Investment Advisors Inc. now owns 187,449 shares of the biopharmaceutical company’s stock valued at $1,968,000 after acquiring an additional 27,294 shares during the last quarter. Institutional investors own 55.44% of the company’s stock.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product.

Get a free copy of the Zacks research report on Sucampo Pharmaceuticals (SCMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sucampo Pharmaceuticals (NASDAQ:SCMP)

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.